SubQSA: A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov) - Oct 27, 2026 - P2 | N=64 | Active, not recruiting | Sponsor: Sanofi | Recruiting ➔ Active, not recruiting
Enrollment closed • Hematological Malignancies • Multiple Myeloma • Oncology
|